Crescent Biopharma financials
$14.76+1.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q3 '23 Sep 30 | Q2 '23 Jun 30 | Q1 '23 Mar 31 | Q4 '22 Dec 31 | Q3 '22 Sep 30 | Q2 '22 Jun 30 | Q1 '22 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $1.0M | $10.8M | $0.00 | $0.00 | $32.0M | $29.3M | $24.9M | $101.5M | $0.00 | $0.00 | $794.0K |
| Gross profit | $0.00 | $1.0M | $10.8M | $0.00 | $0.00 | $30.9M | $28.3M | $23.8M | $97.5M | $0.00 | $0.00 | -$4.0K |
| Gross margin | — | 100.0% | 100.0% | — | — | 96.3% | 96.3% | 95.5% | 96.1% | — | — | −0.5% |
| Operating income | -$26.4M | -$24.7M | -$91.5M | -$25.9M | -$21.0M | $12.8M | $5.0M | $6.7M | $34.8M | -$5.2M | -$5.7M | -$14.7M |
| Net income | -$22.7M | -$21.3M | -$81.1M | -$20.9M | -$19.0M | $4.0M | $1.9M | $2.2M | -$29.9M | -$4.9M | $51.6M | -$14.5M |
| Net margin | — | −2046.4% | −747.5% | — | — | 12.4% | 6.3% | 9.0% | −29.5% | — | — | −1830.7% |
| Diluted EPS | $-0.74 | $-0.70 | $-3.96 | $-1.27 | $-4.93 | $0.05 | $0.02 | $0.03 | $-0.14 | $-2.40 | $24.60 | $-6.90 |
| EBITDA | -$26.3M | -$24.7M | -$91.4M | -$25.9M | -$21.0M | $13.0M | $5.3M | $6.9M | $35.7M | -$5.1M | -$5.6M | -$14.6M |
| Operating cash flow | -$19.5M | -$8.9M | -$26.7M | -$17.5M | -$16.4M | $7.6M | $4.5M | $10.4M | $42.3M | -$7.3M | -$12.3M | -$12.1M |
| Free cash flow | -$19.5M | -$9.1M | -$26.9M | -$18.1M | -$16.5M | $5.6M | $2.1M | $8.7M | $37.3M | -$7.3M | — | — |
| Diluted shares | 30.5M | 30.4M | 20.5M | 16.5M | 3.9M | 78.9M | 78.9M | 78.9M | 208.3M | 2.1M | 2.1M | 2.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $171.6M | $189.2M | $213.2M | $133.3M | $152.6M | $2.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $182.8M | $199.1M | $240.3M | $138.3M | $157.4M | $10.0M |
| Total liabilities | $19.5M | $15.3M | $37.3M | $21.6M | $18.2M | $6.4M |
| Shareholders' equity | $163.3M | $183.8M | $203.0M | $116.6M | $139.3M | -$29.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology